Related Experiment Videos
Chronic myelogenous leukemia: molecular diagnostic considerations
1Department of Laboratory Medicine and Pathology, University of Minnesota Medical School, Minneapolis 55455-0385.
Human Pathology
|June 1, 1994
Summary
Chronic myelogenous leukemia (CML) is often linked to the Philadelphia chromosome (Ph1). Molecular tests like PCR can detect the BCR/c-abl gene fusion, aiding CML diagnosis.
Area of Science:
- Hematology
- Oncology
- Molecular Biology
Background:
- Chronic myelogenous leukemia (CML) is a myeloproliferative neoplasm.
- Philadelphia chromosome (Ph1) positivity is observed in 95% of CML cases.
- The Ph1 chromosome results from a translocation between chromosomes 9 and 22, forming the BCR/c-abl fusion gene.
Purpose of the Study:
- To review the role of the BCR/c-abl fusion gene in CML pathogenesis.
- To discuss molecular diagnostic methods for detecting the BCR/c-abl rearrangement.
- To evaluate the clinical utility of molecular tests in CML management.
Main Methods:
- Cytogenetic analysis for Philadelphia chromosome detection.
- Southern blot hybridization for identifying gene rearrangements.
- Polymerase Chain Reaction (PCR) for sensitive detection of the BCR/c-abl transcript.
Main Results:
- The BCR/c-abl fusion gene is a critical molecular driver in CML.
- Molecular tests offer high sensitivity and specificity for detecting the BCR/c-abl rearrangement.
- These tests serve as valuable adjuncts to traditional cytogenetics.
Conclusions:
- The BCR/c-abl fusion gene is essential for CML development.
- Molecular diagnostic techniques are crucial for accurate CML diagnosis and monitoring.
- These methods enhance the clinical management of CML patients.